Opendata, web and dolomites

SYNKIT SIGNED

Synthetic Natural Killer Cells for Immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SYNKIT project word cloud

Explore the words cloud of the SYNKIT project. It provides you a very rough idea of what is the project "SYNKIT" about.

human    insights    transferred    expand    absence    death    intrinsic    recipient    tumours    cells    shelf    triggers    lack    rejection    pave    deficient    nk    ipsc    natural    efficacy    anti    stem    generation    hla    unravelled    engineering    therapies    reduce    allogeneic    transfer    functional    ipscs    urging    education    modulate    strategy    prevent    successful    underlying    laboratory    deletion    setting    limited    differentiation    eliminate    thereby    leukocyte    combat    complete    ink    poor    ing    possess    cancer    molecular    capacity    modulates    option    attractive    ligands    impaired    immunotherapy    disarming    allogenicity    cell    pluripotent    genetic    platform    diminishing    introduction    synthetic    treatment    engineered    escape    killer    immune    host    function    self    off    innovative    tailor    vitro    tumour    mechanism    limitations    infusion    completion    synkit    antigen    recognition    persistence    missing    worldwide    bottlenecks    broad   

Project "SYNKIT" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 191˙852 €
 EC max contribution 191˙852 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-07-01   to  2022-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 191˙852.00

Map

 Project objective

'Cancer remains a leading cause of death worldwide, urging for innovative therapies. Infusion of natural killer (NK) cells, which possess an intrinsic capacity to eliminate cancer cells, is a promising treatment option for various tumours. Genetic engineering of NK cells before transfer allows to specifically tailor and modulate their anti-tumour responses. One particularly attractive strategy for broad implementation of NK cell immunotherapy in an “off-the-shelf” setting is to expand large numbers of NK cells from induced pluripotent stem cells (iPSCs). However, this approach is limited by two main bottlenecks: i) poor persistence of allogeneic iPSC-derived NK (iNK) cells due to rejection by the recipient immune system and ii) impaired functionality due to failure to achieve complete differentiation in vitro. The SYNKIT project seeks to address both of these current limitations through genetic engineering of iNK cells for increased persistence and function. Deletion of human leukocyte antigen (HLA) 'self-ligands' allows the transferred cells to escape from host T cells. However, absence of HLA also triggers “missing-self” recognition and rejection by host NK cells. In addition, new insights from the host laboratory into the molecular mechanism underlying NK cell education have unravelled a pathway of functional disarming in NK cells that lack self-ligands, further diminishing the anti-tumour efficacy of HLA-deficient NK cells. In SYNKIT, I will use HLA-deficient iNK cells as a platform to assess how introduction of synthetic self-ligands modulates the allogenicity and functionality of iNK cells. The overall goal of SYNKIT is to identify synthetic self-ligands, which reduce recognition by the host immune system and yet prevent functional disarming of the engineered iNK cells, thereby resulting in optimised anti-tumour function. Successful completion of SYNKIT will pave the way for development of next generation immunotherapy to more effectively combat cancer. '

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYNKIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYNKIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GenEl (2020)

General readout electronics for cross-sectoral application in European research infrastructure

Read More  

LipTransProMet (2019)

The multi-omics role of lipid transfer proteins in lipid metabolism

Read More  

TOPOCIRCUS (2019)

Simulations of Topological Phases in Superconducting Circuits

Read More